Who is sponsoring NCT04139967?

NCT04139967 is sponsored by University of Rochester.

What drugs are being tested in NCT04139967?

Interventions in NCT04139967: Short course radiation therapy.

What condition does NCT04139967 study?

NCT04139967 studies Cancer, Rectal.

Is NCT04139967 still recruiting?

NCT04139967 is currently terminated. Last updated 14 July 2023.

Last reviewed 2023-07-14 · How we verify

NCT04139967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer

Terminated NA Last updated 14 July 2023

What this trial tests

NA trial testing Short course radiation therapy in Cancer, Rectal in 2 participants. Terminated before completion.

Timeline

20 January 2020

Primary endpoint
3 August 2022

3 August 2022

Quick facts

Lead sponsor	University of Rochester
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	20 January 2020
Primary completion	3 August 2022
Estimated completion	3 August 2022
Sites	1 location across United States

Drugs / interventions tested

Short course radiation therapy

Conditions studied

Cancer, Rectal — all drugs for Cancer, Rectal →

Sponsor

University of Rochester

Who can join

70 and older, any sex, with Cancer, Rectal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will help determine if a short course of radiation therapy is effective to treat rectal cancer in older patients. A shorter course of radiation treatment may be better tolerated than a longer course or surgery for the treatment of rectal cancer in the elderly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Short course radiation therapy

Trials testing the same drug.

NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT06392906 — Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) · Phase 3 · recruiting

Other recruiting trials for Cancer, Rectal

Currently open trials in the same condition.

NCT06236633 — Safety & Efficacy of Ischemic Preconditioning by Embolization of the Inferior Mesenteric Artery in Surgery for Tumors of · NA · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04139967 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 14 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04139967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing